Pan-PIM Kinase Inhibition Provides a Novel Therapy for Treating Hematological Cancers.
Garcia PD et al. Clin Cancer Res. 2014 Jan 28. [Epub ahead of print].

Mechanisms and consequences of constitutive NF-κB activation in B-cell lymphoid malignancies.
Nagel D et al. Oncogene. 2014 Jan 27. doi: 10.1038/onc.2013.565. [Epub ahead of print].

Cyclin D1 Amplification in Multiple Myeloma Is Associated With Multidrug Resistance Expression.
Sewify EM et al. Clin Lymphoma Myeloma Leuk. 2014 Jan 25. pii: S2152-2650(13)00250-4. doi: 10.1016/j.clml.2013.07.008. [Epub ahead of print].

Dickkopf-1 as a mediator and novel target in malignant bone disease.
Rachner TD et al. Cancer Lett. 2014 Jan 22. pii: S0304-3835(14)00036-6. doi: 10.1016/j.canlet.2014.01.010. [Epub ahead of print].

Defining and targeting myeloma stem cell-like cells.
Abe M et al. Stem Cells. 2014 Jan 22. doi: 10.1002/stem.1643. [Epub ahead of print].

GSK3-mediated MAF phosphorylation in multiple myeloma as a potential therapeutic target.
Herath NI et al. Blood Cancer J. 2014 Jan 17;4:e175. doi: 10.1038/bcj.2013.67.

Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy.
Lohr JG et al. Cancer Cell. 2014 Jan 13;25(1):91-101. doi: 10.1016/j.ccr.2013.12.015.

From anecdote to targeted therapy: the curious case of thalidomide in multiple myeloma.
Licht JD et al. Cancer Cell. 2014 Jan 13;25(1):9-11. doi: 10.1016/j.ccr.2013.12.019.

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma.
Bolli N et al. Nat Commun. 2014 Jan 16;5:2997. doi: 10.1038/ncomms3997.

Osteoblastic niche supports the growth of quiescent multiple myeloma cells.
Chen Z et al. Blood. 2014 Jan 14. [Epub ahead of print].

NF-κB pathways in hematological malignancies.
Gasparini C et al. Cell Mol Life Sci. 2014 Jan 14. [Epub ahead of print].

Inhibitor of apoptosis proteins (IAPs) as therapeutic targets in multiple myeloma (MM).
Ramakrishnan V et al. Leukemia. 2014 Jan 9. doi: 10.1038/leu.2014.2. [Epub ahead of print].

Apoptotic Machinery Diversity in Multiple Myeloma Molecular Subtypes.
Gomez-Bougie P et al. Front Immunol. 2013 Dec 23;4:467. eCollection 2013.

CD38 and bone marrow microenvironment.
Chillemi A et al. Front Biosci (Landmark Ed). 2014 Jan 1;19:152-62.

Mechanism of immunomodulatory drugs’ action in the treatment of multiple myeloma.
Chang X et al. Acta Biochim Biophys Sin (Shanghai). 2013 Dec 29. [Epub ahead of print].

Macrophages in multiple myeloma.
Ribatti D et al. Immunol Lett. 2013 Dec 24. pii: S0165-2478(13)00224-1. doi: 10.1016/j.imlet.2013.12.010. [Epub ahead of print].

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma.
Gkotzamanidou M et al. Med Sci Monit. 2013 Dec 20;19:1188-94. doi: 10.12659/MSM.889752.